NASDAQ:ALDX - Aldeyra Therapeutics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.76 -0.21 (-2.63 %)
(As of 02/19/2019 07:57 AM ET)
Previous Close$7.97
Today's Range$7.50 - $8.02
52-Week Range$6.75 - $16.70
Volume333,843 shs
Average Volume186,648 shs
Market Capitalization$203.65 million
P/E Ratio-5.54
Dividend YieldN/A
Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. Aldeyra Therapeutics, Inc. has a collaborative research agreement with Janssen Research & Development, LLC for the development of novel immune-modulating drugs for systemic inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is headquartered in Lexington, Massachusetts.

Receive ALDX News and Ratings via Email

Sign-up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:ALDX



Sales & Book Value

Annual SalesN/A
Book Value$2.07 per share


Net Income$-22,340,000.00


Market Cap$203.65 million

Aldeyra Therapeutics (NASDAQ:ALDX) Frequently Asked Questions

What is Aldeyra Therapeutics' stock symbol?

Aldeyra Therapeutics trades on the NASDAQ under the ticker symbol "ALDX."

How were Aldeyra Therapeutics' earnings last quarter?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) announced its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.43) by $0.03. View Aldeyra Therapeutics' Earnings History.

When is Aldeyra Therapeutics' next earnings date?

Aldeyra Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, April 4th 2019. View Earnings Estimates for Aldeyra Therapeutics.

What price target have analysts set for ALDX?

7 analysts have issued 12 month price objectives for Aldeyra Therapeutics' shares. Their predictions range from $23.00 to $36.00. On average, they expect Aldeyra Therapeutics' share price to reach $30.40 in the next twelve months. This suggests a possible upside of 291.8% from the stock's current price. View Analyst Price Targets for Aldeyra Therapeutics.

What is the consensus analysts' recommendation for Aldeyra Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aldeyra Therapeutics in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aldeyra Therapeutics.

What are Wall Street analysts saying about Aldeyra Therapeutics stock?

Here are some recent quotes from research analysts about Aldeyra Therapeutics stock:
  • 1. According to Zacks Investment Research, "Aldeyra Therapeutics, Inc. is a biotechnology company. The company's products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. " (1/3/2019)
  • 2. Cantor Fitzgerald analysts commented, "Aldeyra develops a platform of aldehyde trap therapies for the potential treatment of inflammation in ocular diseases and inborn errors of aldehyde metabolism. We believe Aldeyra’s is poised for several near term catalysts over the next 12 months. Valuation Summary We arrive at our 12-month price target of $30/share by assessing the after-tax, risk- adjusted NPV of future cash flows from reproxalap, the platform and year-end 2019 cash." (11/14/2018)
  • 3. Canaccord Genuity analysts commented, "We are expecting a late 3Q18/early 4Q18 data update for the Phase 2b dry eye disease trial, which we are expecting to show changes across multiple standard signs and symptom endpoints. We remind investors that while statistical significance over vehicle (superiority) would be ideal, the trial is not powered to detect superiority since vehicle has not previously been tested against reproxalap. However, since the vehicle is an “aqueous” formulation, we do not expect significant activity from the vehicle arm. Furthermore, the data update would help us assess the proper dosing and endpoints (symptom and sign) for the Phase 3 trial. We remind investors that the FDA is likely to look for one replicated sign and one replicated symptom improvement as basis of approval." (8/10/2018)

Has Aldeyra Therapeutics been receiving favorable news coverage?

Media coverage about ALDX stock has been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aldeyra Therapeutics earned a daily sentiment score of 1.4 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next few days.

Who are some of Aldeyra Therapeutics' key competitors?

Who are Aldeyra Therapeutics' key executives?

Aldeyra Therapeutics' management team includes the folowing people:
  • Dr. Todd C. Brady, Chief Exec. Officer, Pres and Director (Age 46)
  • Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer and Treasurer (Age 59)
  • Dr. David J. Clark M.D., M.R.C.P., A.F.P.M., Chief Medical Officer (Age 53)
  • Ms. Mary Taylor M.P.H., Sr. VP of Regulatory Affairs (Age 59)

Who are Aldeyra Therapeutics' major shareholders?

Aldeyra Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include 683 Capital Management LLC (5.31%), BlackRock Inc. (4.95%), Sphera Funds Management LTD. (4.69%), Millennium Management LLC (2.51%), Prosight Management LP (1.54%) and Northern Trust Corp (0.99%). View Institutional Ownership Trends for Aldeyra Therapeutics.

Which major investors are selling Aldeyra Therapeutics stock?

ALDX stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Millennium Management LLC, Kepos Capital LP, Dimensional Fund Advisors LP, Hikari Power Ltd, Falcon Point Capital LLC and Stifel Financial Corp. View Insider Buying and Selling for Aldeyra Therapeutics.

Which major investors are buying Aldeyra Therapeutics stock?

ALDX stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Prosight Management LP, Sphera Funds Management LTD., Geode Capital Management LLC, Squarepoint Ops LLC, Northern Trust Corp, Connor Clark & Lunn Investment Management Ltd. and 683 Capital Management LLC. View Insider Buying and Selling for Aldeyra Therapeutics.

How do I buy shares of Aldeyra Therapeutics?

Shares of ALDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Aldeyra Therapeutics' stock price today?

One share of ALDX stock can currently be purchased for approximately $7.76.

How big of a company is Aldeyra Therapeutics?

Aldeyra Therapeutics has a market capitalization of $203.65 million. The biotechnology company earns $-22,340,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis. Aldeyra Therapeutics employs 12 workers across the globe.

What is Aldeyra Therapeutics' official website?

The official website for Aldeyra Therapeutics is

How can I contact Aldeyra Therapeutics?

Aldeyra Therapeutics' mailing address is 131 HARTWELL AVENUE SUITE 320, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-761-4904 or via email at [email protected]

MarketBeat Community Rating for Aldeyra Therapeutics (NASDAQ ALDX)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  269 (Vote Outperform)
Underperform Votes:  196 (Vote Underperform)
Total Votes:  465
MarketBeat's community ratings are surveys of what our community members think about Aldeyra Therapeutics and other stocks. Vote "Outperform" if you believe ALDX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALDX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2019 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel